Mechanistically, PRMT1 recruits the SWI/SNF chromatin remodeling complex via direct interaction with SMARCC1, leading to the transcriptional activation of insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2), which enhances CBP resistance and tumor growth. The gene discussed is PRMT1; the disease is neoplasm.